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Abstract: 
Non-alcoholic fatty liver disease (NAFLD) consists of a range of complication. The disease describes clinical , para clinical and 
pathological conditions from simple steatosis in non-alcoholic steato hepatitis (NASH) to fibrosis, cirrhosis and hepato cellular 
carcinoma. Therefore, it is of interest to evaluate the grade of fatty liver and Liver Function Test in NAFLD patients. We collected 
samples and data from 80 patients referred to gastrointestinal clinic of Emam Reza hospital with sonography diagnosed NAFLD 
and were evaluated in two groups in a randomized clinical trial. The effects of L-Carnitine (500 mg) prescription twice a day on 
liver enzymes and echogenicity changes in case group was documented and compared with the control group. The mean age of the 
patients was 40.7±8 in the age range of 25 to 62 years old with 66 (82.5%) male and 14 (17.5%) female patients. Data show that fatty 
liver changes were not significantly different in the two groups (P=0.23). It is observed that the ALT was the only enzyme with 
significant changes (P=0.01) after a 24-week interval. It is also noted that the difference in fatty liver sonographic grading was also 
significant in the two groups (P=0.0001). Thus, proper therapeutic protocols can be adopted beside diet and weight loss to control 
the disease trend in consideration to the significant changes observed both in enzymatic levels and sonographic grading between 
the two groups of patients with NAFLD.  
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Background:  
Non-alcoholic Fatty Liver Disease is defined as accumulated 
lipid in hepatocytes, more than 5% of liver weight, in the 
absence of virus infections and alcohol usage (more than 30 
gmper day),including a wide spectrum of liver damage, on the 
one hand hepatic steatosis and the other hand non-
alcoholicSteatohepatitis related to fibrosis,necrosis, 
inflammation and hepatocellular cancer [1-3]. Fibrosis caused 
by NASH has seen in 40% of very fat patients[4]. According to a 
theory called ''two-hit'',the changing and progressing of the 
simple steatosis to hepatic steatosis and advanced fibrosis is 
caused by two hits [5], in which the first hit leads to insulin-
resistant accumulated lipid in the liver and the second one due 
to the accumulatedlipid in liver causes oxidative stress and then 
facilitatedinflammation, progressing steatosis and fibrosis [6, 7]. 
This disease led to hepatic cirrhosis and finally death [8]. The 
prevalence of NAFLD in20-30% of general people in the 
Western countries, and the prevalence of NASH in 3-5% of them 
is estimated [9, 10]. Whereas,the prevalence of this disease was 
less in Asian countries but increased because of mellitus 
diabetes, metabolic syndrome and changing life style [11]. Also 
the prevalence of that among male is more than female, it`s 
common inwomen especially after menopause [12]. Most of 
people who were receiving treatment for this disease, were 
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diagnosed with high level of ALT and AST enzymes in which 
the serum level of ALT is more than AST, so ALT to AST ratio is 
less than 1 [13]. This disease is the most common reason for 
abnormal values of liver enzymes in current decades [14]. We 
can point to the other laboratory disorders such as fasting blood 
sugar,LDL-TG, etc [15]. In fact,there must be an inflammatory 
and damage intensity of parenchyme and fibrosis ranking 
system in order to determine the prognosis and evaluated effect 
of treat interventions during disease [16]. Currently, there is 
nocertain treatment for NAFLD,so it seems necessary to find 
new treatment approach,replacing or helping current treatment 
for fatty liver. L-Carnitine with chemical formula (B-hydroxy-N- 
TrimetylAminobutyric Acid) has animportant role in fatty acids 
Beta-oxidation with long strain in mitochondria and energy 
synthetis in cell [17, 18], which finally causes fatty oxidation and 
storing glycation [19]. With respect to antioxidativequality of L-
carnitine and improving the endothelial function [20, 21], we 
were to evaluate the effect of L-carnitine in and sonographic 
evidences in treatment of non-alcoholic fatty liver disease. 
 
Methodology: 
Population 
In a randomized and controlled clinical trial study, we 
examined 80 patients’ withgastroenterologydisorders in Emam 
Reza and Sheikh Alrais centers in Tabriz. We then divided them 
into control and intervention groups each including 40 patients, 
with known sonographic evidences based on Liver steatose, 
while other causes of fatty liver had been rejected. 
 
Study entrance criteria 
The patient criteria include NAFLD with liver steatose in 
sonography of the liver having liver function test with greater 
than 40mg/dl.   
 
Study exit criteria 
Diabetic patients 
Other reasons increasing liver enzymes: viral 
infections,hereditary diseases such as hemachromatosis, 
Wilson`s disease, auto immunity hepatitis and drugs causing 
drug hepatitis Alcohol consumption more than 10 gr for female 
and 20 gr for male Sonographic and laboratory evidences 
confirming cholestatic Diseasestriglyceride more than 500 
mg/dl in individuals 
 
ClinicalTrial 
This study has been done onJune 2012-July 2014. At first 
patients’ height and weight by stadiometer and Seca scales with 
0.1kg and 0.5 cm precisionrespectively and BMI by standard 
formula have been measured [22]. There was a questionnaire for 
each patient including personal information,gender,age, past 
experience of diseasesespecially high blood pressure, 
overweight, hyper lipidemia, ALT and AST quantities and 
sonographic evidences.Exercising and on low fat diet were 
recommended to both groups. Group A patients received 
treatment L-carnitine tablet 250mg every 12 hours and group B 
was considered as controlgroup.In 24 weeks,ALT and AST test 
and sonographyof liver were done in order to determine fatty 
liver`s grade. 
 
Sonography and LaboratoryTests 
After and before intervention,sonography of patients in each 
group was done by radiologist who was not aware of 
biochemical liver tests, with Siemens G40 and pruvconex, and 
3.46 MHz frequency after 8 hours fasting.The fatty liver grade 
was classified as Grade I,Grade II, and Grade III according to 
sonographiccriteria (Figure 1). After 12-14 hours fasting,ALT 
and AST quantities for all patients at the first and end of the 
period were measured by Pars Azmoon kit (made in Iran) and 
auto analyzer (Hitachi 747, Japan). 
 
 
Figure 1: The grading of accumulated lipid intensity in liver 
according to sonographic evidences 
 
Statistical Analysis 
The data was analyzed and compared by SPSS version 16 using 
Qui-Square forqualitative variables and Student T-test for 
quantitativevariables and registered byMean ±SD into 
percentage and frequency. 
 
 
Figure 2: Comparison of sample frequency in different age 
groups, between two groups 
 
Results: 
On the whole in 80 patients with NAFLD, 66individuals were 
men (82.5 %) and 24 individualswere women (17.5 %). They 
were divided into two groups A and B,so that there were 23 
men (82.5 %) and 7 women(17.5 %) in each group. After the 
analysis, there was no significant statistical difference between 
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two groups (p=0.61).The average age in all patients was40.7±8 
years old which was in the range of 25-36 years (Figure 2). The 
average age in group A and group B was 40.3±7.8and 41.1±8.3 
years old respectively. The age difference between twogroups of 
patients was not significant (p=0.65). The most frequency of 
patients’age was 30-41 years old and the least frequency was 
+50 years old. Patients were divided into 4 groups according to 
sonographic evidences (Figure 1). Therefore,before intervention, 
there were 7 individuals Grade I, 31 individuals Grade II  and  2 
individuals Grade III in group A Table 1 (see supplementary 
material),  22 individuals Grade I, 17 individuals Grade II and 1 
individual Grade III in group B (Table 1).Variances after and 
before interventionin group A were significant in ALT,AST, 
BMI, weight and sonographic grade (Table 1). Variances after 
and before intervention in group B in BMI and weight was 
significant, but in ALT,AST and sonographic grade was 
significant (Table 1). 
 
Discussion: 
NAFLD was identified for the first time in people without 
alcohol usage experience in 1980 [23]. In fact, this disease 
includes a wide range of disorders from accumulated lipid in 
big vesicular form to accumulated lipidwith inflammation, 
cirrhosis and hepatic damage [24]. In fact, when NAFLD 
appears that fat comprises 5-10% of liver’s weight [25-27]. The 
prevalence of this is 34-46 % in adults, although the prevalence 
of it is 21.5-31.5 % in Iran [28-30]. There is have been no certain 
treatment for NAFLD so far, but losing weight, 
controllingmetabolic syndromes like diabetes and 
hyperlipidemia, taking antioxidant drugs like Vitamin D and 
those which are sensitive to insulin are recommended [31, 32]. It 
is suggested to take Thiazolidinedione family drugs such as 
Pioglitazone and Rosiglitazone, although it calls for more 
investigations in comprehensiveresearch projects [33]. In the 
present study, the effects of L-carnitine prescription on Liver 
function test and sonographic evidences were evaluated. The 
results indicated decrease in weight and BMI,after and before 
intervention, in both groups; moreover, this decreasewas 
significant in group A. InBahrami et al.,2003 study which was 
done on 53 NAFLD patients, the average weight of patients 
wasmore than control group,so that patients had high BMI and 
10 % weight addition to their idea weight [34]. In our study 
before any intervention, both groups were homogenized in 
terms of BMI and weight, so that there was no significant 
statisticaldifference. The role of BMI and weight in fatty liver 
hasbeen the topic of many studies. In the past, BMI was the 
more important independent predictor agent of accumulated fat 
in liver [35, 36]. Other researcheshave accentuated that the 
peripheral accumulated lipid is a more important predictor 
agent in comparison with BMI [37, 38]. So according to the 
significant reduction in BMI and weight effected by taking  L-
carnitinedaily in intervention group, this drug can be 
considered as an effective drug and can be prescribed for 
NAFLD patients . In this present, the reduction of serum level of 
Liver enzymes andsonographic grade was significant in both 
groups, but 9 individuals in group A, after 24-week period, had 
normal sonographic grade. According to these results, it can be 
claimed that L-carnitine 500mg prescribed cannot be considered 
as an absolute treatmentto improve serum levels of Liver 
enzymes and sonographic grade in NAFLD patients. While in 
the results of Malaguarnera et al.,2010 study that evaluated 
laboratory parameters,BMI,weight and histological observed 
Liver after taking L-carnitine 1000mg twice  in 24 
weeks,indicated CRP, TNF-α and lipid profile reduction and 
significant improvement in histological fatty Liver [39]. The 
difference between the results ofMalaguarnera`s study and this 
one can be because of the drug dosage during the treatment. In 
Biefort et al.,2006 study which evaluated  the effect of 45mg 
Piolitazone in 24 weeks for fatty Liver treatment, the reduction 
in lipid profile, ALT  and sonographic view was significant, in 
contrast AST quantity reduction was not significant [40]. We can 
refer to Hong & Lee `s study about the effect of other drugs on 
improving NAFLD patients in which anyone presented  a 
different report about improving Liver function by taking  
Resveratrol [41, 42]. In Celinski et al.,2014  has claimed that 
melatonin can be used in the treatment ofNAFLD especially 
metabolism of lipid disorders,hyper triglyceridemia and hyper-
LDL cholesterolemia [43]. 
 
Conclusion: 
A suitable treatment protocol with L-carnitinecanbeadvised, so 
the disease can be well controlled as per significant reduction of 
liver enzymes and improving sonographic grade in the 
comparison between both groups with NAFLD, besides losing 
weight and a proper diet. 
 
Acknowledgment: 
This study is a part of a thesis in  sub specialty degree  section  
registered by theResearchEthicsCommitteeapproval with89/5-
13/10  code at  the  Medical university of Tabriz  and with  
N11RCT201102235893 code at the Clinical Trial website of  
Ministry of health of Iran. Hereby we would like to appreciate 
the support of Research Centerfor Gastroenterology andLiver of 
Medical University ofTabriz. 
 
References: 
[1] Byrne CD et al.  Clin Sci. 2009 116: 539 [PMID: 19243311] 
[2] Bahrololumi SS et al.  Razi Journal of Medical Sciences. 2014 
20: 66 
[3] Neuschwander‐Tetri BA et al. Hepatology. 2003 37: 1202 
[PMID: 12717402] 
[4] Harrison SA & Di Bisceglic AM, Drugs.  2003 63: 2379 
.[PMID: 14609346] 
[5] Day CP & James OF, Gastroenterology. 1998 114: 842 .[PMID: 
9547102] 
[6] Petta S et al. Digestive and Liver Disease. 2009 41: 615 .[PMID: 
19223251] 
[7] Videla LA et al. Free Radical Biology and Medicine. 2004 37: 
499 .[PMID: 15454290] 
[8] McClain CJ et al. Alcohol. 2004 34: 67 
[9] Bellentani S et al. Digestive diseases. 2010 28: 155 .[PMID: 
20460905] 
[10] Ruhl CE et al. Clinics in liver disease. 2004 8: 501. 
[11] Ahad Eshraghian M et al. Archives of Iranian medicine. 2013 
16: 584.[PMID: 24093139] 
[12] Zolfaghari H et al. Journal of Isfahan Medical School. 2014 32: 1 
[13] Matteoni CA et al. Gastroenterology. 1999 116: 1413 .[PMID: 
10348825] 
[14] Obika M et al. Experimental diabetes research. 2012 2012: 
145754.[PMID: 22110476] 
[15] Chen SM et al. Journal of the Chinese Medical Association. 2008 
71: 551 [PMID: 19015052] 
[16] Laroussi N et al. Gastroenterologie clinique et biologique. 2002 
26: 475.[PMID: 12122357] 
BIOINFORMATION open access 
 
ISSN 0973-2063 (online) 0973-8894 (print)   
Bioinformation 10(9): 575-579 (2014) 578  © 2014 Biomedical Informatics 
 
[17] Dokmeci D et al. Cell biochemistry and function. 2007 25: 611 
.[PMID: 16883624] 
[18] Ramezani M et al. Qom University of Medical Sciences Journal. 
2012 6: 9 
[19] Arazi H et al. Tehran University of Medical Sciences. 2013 71: 
59 
[20] Gülçin İ et al. Life Sciences. 2006 78: 803 .[PMID: 16253281] 
[21] Mansour HH et al. Pharmacological research. 2006 54: 165 
.[PMID: 16757176] 
[22] Tobias DK et al. New England Journal of Medicine. 2014 370: 
233  [PMID: 24428469] 
[23] Ekhlasi G et al. Razi Journal of Medical Sciences. 2013 20: 30 
[24] McCullough AJ et al. Clinics in liver disease. 2004 8: 521 
.[PMID: 15331061] 
[25] Ghaemi A et al. Iranian Journal of Nutrition Sciences & Food 
Technology. 2013 8: 123. 
[26] Mensink RP et al. Current opinion in lipidology. 2008 19: 25 
[27] Zivkovic AM et al. The American journal of clinical nutrition. 
2007 86: 285 [PMID: 17684197] 
[28] Williams CD et al. Gastroenterology. 2011 140: 124 .[PMID: 
20858492] 
[29] Lankarani KB et al. Hepatitis monthly. 2013 13: 9248 [PMID: 
23922564] 
[30] Browning JD et al. Hepatology. 2004 40: 1387 .[PMID: 
15565570] 
[31] Faghihzadeh F et al. Iranian Journal of Nutrition Sciences & 
Food Technology. 2014 8: 40. 
[32] Yki-Järvinen H et al. Current Opinion in Clinical Nutrition & 
Metabolic Care. 2010. 13: 709 [PMID: 20842026] 
[33] Brunt EM, Semin Liver Dis. 2001 21: 3 .[PMID: 11296695] 
[34] Bahrami H  .et al. BMC gastroenterology. 2003 3: 27.[PMID: 
14561231] 
[35] Angulo P et al. Hepatology. 1999 30: 1356.[PMID: 10573511] 
[36] Rinella ME et al. Liver Transplantation. 2001 7: 409 [PMID: 
11349260] 
[37] Eguchi Y et al. Journal of gastroenterology. 2006 41: 462 
[PMID: 16799888] 
[38] Koda M et al. Journal of gastroenterology. 2007 42: 897.[PMID: 
18008034] 
[39] Malaguarnera M et al. The American journal of 
gastroenterology. 2010 105: 338 [PMID: 20068559] 
[40] Belfort R et al. New England Journal of Medicine. 2006 355: 
2297.[PMID: 17135584] 
[41] Lee ES et al. Archives of pharmacal research. 2010 33: 
925.[PMID: 20607498] 
[42] Poulsen MM et al. Diabetes. 2013 62: 1186.[PMID: 23193181] 
[43] Celinski K et al. J Physiol Pharmacol. 2014 65: 75 [PMID: 
24622832] 
 
Edited by P Kangueane 
Citation:  Somi et al. Bioinformation 10(9): 575-579 (2014) 
License statement: This is an open-access article, which permits unrestricted use, distribution, and reproduction in any medium, 
for non-commercial purposes, provided the original author and source are credited 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BIOINFORMATION open access 
 
ISSN 0973-2063 (online) 0973-8894 (print)   
Bioinformation 10(9): 575-579 (2014) 579  © 2014 Biomedical Informatics 
 
Supplementary material:  
 
Table 1: The variances between intended indexes before and after the intervention in groups A & B 
 
 
 
 
 
 
 
 
 Group A Group B 
Variable Pre-Trial Post-Trial Pre-Trial Post-Trial 
Weight 88.3±13.1 85.8±12.6** 85.2±10.7 84.7±10.2* 
BMI 29.4±3.9 28.6±4** 28.6±3.2 28.4±3.1* 
AST 60.5±28.3 44.9±22.8** 52.6±24.4 39.5±21.1** 
ALT 81.7±40.1 51±23.5** 54.1±17.6 38.4±18.9** 
Grade I 7 (17.5%) 9 (22.5%)* 22(55%) 30 (75%)** 
II 31(77.5%) 22 (55%)* 17(42.5%) 10 (25%)** 
III 2 (5%) ……….* 1(2.5%) ……….** 
Normal ………. 9 (22.5%)* ………. ………** 
Measures: weight= kg, BMI=kg/m2, AST=mg/dl, ALT=mg/dl 
Comparison within group A and within group B according to the values before the treatment: 
* P = NS; ** P < 0.05 
